Atossa Therapeutics Inc
ATOS
Get informed when a big investor buys or sells
+ FollowMarket Cap$22.14M
Close$
$4.80
129.5% upside
Current Fair Value
129.5% upsideUndervalued by 129.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $22.14 Million |
|---|---|
| Enterprise Value | $-3,949,500.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.04 |
| Beta | 1.28 |
| Outstanding Shares | 8,908,511 |
Return
| Return on Equity | -140.55% |
|---|---|
| Return on Assets | -116.81% |
| Return on Invested Capital | -75.02% |
Valuation & Multiples
| P/E Ratio | -0.51 |
|---|---|
| PEG | -63.36 |
| Price to Sales | - |
| Price to Book Ratio | 0.7 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.2 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-0.94
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.92
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 11,300▲ Infinity% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 16.73%▲ 2.35% |
|---|---|
| Total Invested | $2.72M▼ 58.31% |
| Investors Holding | 33▼ 1.00% |
ESG Score
No data
About Atossa Therapeutics Inc
CEO: Steven Quay Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19.